Funding for this research was provided by:
International Myeloma Foundation (IMF-R16103NN)
fondation française pour la recherche contre le myélome et les gammapathies monoclonales
I-SITE NexT (ANR-16-IDEX-0007)
SIRIC ILIAD (INCa-DGOS-Inserm-12558)
Received: 17 August 2020
Accepted: 9 July 2021
First Online: 9 August 2021
: All the samples were obtained from patients enrolled in the different randomized clinical trials implemented by the Intergroupe Francophone du Myelome (IFM); IFM 99-02, IFM 99-06, IFM 2005-01, FIRST/IFM 2007-01, IFM 2007-02, Genomgus Study and IFM 2009 (www.clinicaltrials.gov) or routine practice in France. All patients provided written informed consent prior to sample and data collection. All research procedures conformed to the principles of Helsinki Declaration.
: Not applicable.
: The authors declare that they have no competing interests.